Table 1 Study population characteristics.

	C. trachomatis negative (n = 42)(58%)	C. trachomatis positive (n = 30)(42%)	P-value*
Age, years (median)	18.5	18	0.80
Hormonal contraception			0.73
Injectable	36 (86%)	27 (90%)
Non-injectable	6 (14%)	3 (10%)
No (none)	0 (0%)	0 (0%)
BMI (median)^a	25.39	25.15	0.35
Intra-vaginal practices ^b
Douching	3 (8%)	0 (0%)	0.31
Washing w. water	31 (97%)	26 (93%)	0.91
Washing w. soap	22 (67%)	17 (63%)	0.98
Lifetime # partners (median)	3	2	0.20
Multiple partners^c	22 (61%)	10 (36%)	0.32
Regular condom use^d	25 (76%)	15 (56%)	0.17
BV prevalence			0.10
BV positive	17 (40%)	18 (60%)
BV intermediate	4 (10%)	0 (0%)
BV negative	21 (50%)	12 (40%)
Endocervix Alpha Diversity (Shannon, median)	1.1	1.8	0.28
Vaginal pH (median)	4.7	4.7	0.77
N. gonorrhea positive	2 (0.5%)	7 (23%)	0.02
HPV positive^e	17 (49%)	15 (75%)	0.09

*Chi-squared test (Fisher’s exact test when expected values < 5) for the assessment of association of frequency among groups and the Mann–Whiney U-test for comparison of medians. Unpaired t-test for alpha diversity.
BV; bacterial vaginosis, STI; sexually transmitted infection, OCP; oral contraceptive pills.
^aparticipants had missing information.
^b11 participants had missing information.
^c15 participants had missing information.
^d12 participants had missing information.
^e17 participants had missing information.

Quick links

Search